Behavioral and slice electrophysiological assessment of DREADD ligand, deschloroclozapine (DCZ) in rats

Todd B. Nentwig1,2, J. Daniel Obray1,2, Dylan T. Vaughan1 & L. Judson Chandler1*

Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) have become a premier neuroscience research tool for enabling reversible manipulations of cellular activity following experimenter-controlled delivery of a DREADD-specific ligand. However, several DREADD ligands, e.g., clozapine-N-oxide (CNO), have metabolic and off-target effects that may confound experimental findings. New DREADD ligands aim to reduce metabolic and potential off-target effects while maintaining strong efficacy for the designer receptors. Recently a novel DREADD ligand, deschloroclozapine (DCZ), was shown to induce chemogenetic-mediated cellular and behavioral effects in mice and monkeys without detectable side effects. The goal of the present study was to examine the effectiveness of systemic DCZ for DREADD-based chemogenetic manipulations in behavioral and slice electrophysiological applications in rats. We demonstrate that a relatively low dose of DCZ (0.1 mg/kg) supports excitatory DREADD-mediated cFos induction, DREADD-mediated inhibition of a central amygdala-dependent behavior, and DREADD-mediated inhibition of neuronal activity in a slice electrophysiology preparation. In addition, we show that this dose of DCZ does not alter gross locomotor activity or induce a place preference/aversion in control rats without DREADD expression. Together, our findings support the use of systemic DCZ for DREADD-based manipulations in rats, and provide evidence that DCZ is a superior alternative to CNO.

Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are a chemogenetic tool widely used in neuroscience research to reversibly manipulate neuronal activity1,2. DREADDs are G-protein coupled receptors (GPCRs) that were mutated to shift activation from native ligands to "inert" synthetic ligands that can be experimentally administered. A variety of DREADDs are available, but the most common are the Gi based, hM4Di, and the Gq based, hM3Dq, for inhibitory and excitatory neuronal modulation, respectively3,4. DREADDs are typically expressed through viral vectors delivered locally to brain tissue or via transgenic animals possessing conditional expression of DREADDs. Successful use of DREADDs have been observed in multiple species and across a broad range of applications5–7.

DREADDs offer a powerful method for manipulating cellular activity, however, a notable limitation of this technology is the ligand used for DREADD activation8. The first DREADD ligand that was widely adopted was clozapine-N-oxide (CNO), an “inert” metabolite of the atypical antipsychotic compound clozapine. The initial characterization of DREADDs demonstrated that CNO exhibited negligible (< 1 uM) affinity for an array of GPCRs, whereas, its parent compound, clozapine displayed a broad GPCR binding profile1,9. However, CNO has since been shown to undergo reverse-metabolism to clozapine following systemic administration10,11. Furthermore, several reports have observed that systemic CNO produces off-target effects, presumably due to back-conversion into clozapine, which can penetrate the blood brain barrier11,12. Thus, there is a growing effort to develop DREADD ligands with improved potency and specificity.

A novel DREADD ligand, deschloroclozapine (DCZ) was recently developed and displayed promising results in mice and monkeys13. DCZ appears to have improved binding affinity for hM4Di and hM3Dq DREADDs with reduced off-target GPCR activity compared to other DREADD ligands. In mice and monkeys, systemic DCZ administration rapidly penetrated the brain with negligible metabolite accumulation. Further, DCZ effectively supported DREADD-mediated physiological and behavioral effects at relatively low doses (0.001–0.1 mg/kg) without apparent off-target effects. Overall, DCZ exhibits greater potency and selectivity for muscarinic

1Department of Neuroscience, Medical University of South Carolina, 30 Courtenay St, Charleston, SC 29425, USA.
2These authors contributed equally: Todd B. Nentwig and J. Daniel Obray. *email: chandj@musc.edu
DREADD receptors than other available DREADD ligands, which will likely facilitate a shift towards DCZ use in the neuroscience research community. However, based upon prior issues that arose with DREADD ligands, care must be taken to rigorously test the effects of DCZ for DREADD activation in other species and applications. Therefore, the goal of this study was to assess the efficacy of systemic DCZ for DREADD activation in rats. Our data suggest that systemic DCZ supports hM3Dq- and hM4Di-mediated cellular and behavioral effects in rats and support the use of DCZ for muscarinic DREADD receptors over existing DREADD ligands.

Results

The goal of the present study was to examine the effectiveness of systemic DCZ for DREADD-based chemogenetic manipulations in behavioral and slice electrophysiological applications in rats. The approach involved examination of hM3Dq-mediated cFos induction by DCZ, acute slice electrophysiology to compare the effects of DCZ and CNO on hM4Di-mediated inhibition of evoked action potential firing, hM4Di-mediated inhibition of an amygdala-dependent alcohol drinking behavior by DCZ, and assessment of the effects of DCZ on gross locomotor activity and place conditioning.

DCZ-mediated chemogenetic activation elicits selective cFos induction. The first set of experiments assessed whether DCZ is sufficient to support chemogenetic induced of cFos expression. Animals received unilateral injections of an excitatory DREADD (hM3Dq) and were injected with either DCZ or saline and sacrificed to examine cFos induction in hM3Dq + cells. An unpaired t-test indicated that both saline and DCZ-treated rats exhibited similar numbers of virally transduced hM3Dq.mCherry + cells (t_{5} = 0.9947, p = 0.3655; Fig. 1A, D). However, DCZ-treated rats exhibited significantly more cFos + cells than saline controls (t_{5} = 2.593, p = 0.0486; Fig. 1B, E). In addition, in DCZ-treated rats, no cFos + cells were observed in the opposite hemisphere that was not injected with hM3Dq virus, indicating that DCZ alone does not induce cFos expression. Moreover, DCZ-treated rats also exhibited a significantly higher percentage of mCherry + cells that co-expressed cFos relative to saline controls (t_{5} = 16.66, p < 0.0001; Fig. 1C, F). Overall, these results demonstrate that DCZ induced robust cFos expression in cells expressing excitatory DREADD receptors without non-specific cFos induction.

Characteristics of DCZ in slice electrophysiology preparations. The next set of experiments compared the potency of DCZ with the commonly used DREADD ligand, CNO, for chemogenetic inhibition of neural activity in an acute slice electrophysiology preparation. Neurons in the central amygdala (CeA) expressing the hM4Di underwent whole-cell patch clamp recordings (Fig. 2A) to determine potency of DCZ and CNO on inhibiting firing rate (Fig. 2B). A mixed-effects ANOVA with concentration and drug as factors revealed...
significant main effects of concentration ($F(2.343, 16.40) = 18.09, p < 0.0001$) and drug ($F(1,7) = 10.07, p = 0.0156$), indicating that increasing concentrations of drug further inhibited firing rate and that DCZ produced greater inhibition of firing rate relative to CNO. In addition, there was also a significant drug × concentration interaction ($F(4, 28) = 3.702, p = 0.0153$). Post-hoc analysis revealed that DCZ produced significant inhibition of firing rate at 125, 250 ($p = 0.0549$), 500 and 1000 nM concentrations, relative to baseline, whereas CNO significantly suppressed firing only at the 1000 nM concentration (all $p$ values < 0.05), which suggests that DCZ was more potent than CNO at reducing firing rate in hM4Di + neurons. We separately plotted action potential firing during baseline and maximal drug concentration (1000 nM) conditions for both DCZ (Fig. 2C) and CNO (Fig. 2D). Paired t-tests indicated that both DCZ ($t_{4} = 6.318, p = 0.0032$) and CNO ($t_{4} = 4.382, p = 0.0220$) significantly reduced action potential firing at the 1000 nM concentration. As a complementary measure, changes in membrane potential were analyzed from the drug dose–response curve recordings (Fig. 2E). A mixed-effects ANOVA with concentration and drug as factors revealed significant main effects of concentration ($F(1.898, 13.28) = 8.463, p = 0.0047$) and drug ($F(1,7) = 7.804, p = 0.0268$), and a significant concentration by drug interaction ($F(4, 28) = 3.055, p = 0.0330$). Post-hoc analysis revealed that DCZ produced a significant reduction in membrane potential at the 1000 nM concentration, relative to the zero concentration. Overall these findings suggest that DCZ is more effective at functionally inhibiting hM4Di-expressing neurons than CNO.

**DCZ-mediated chemogenetic inhibition of the central amygdala reduces dependent ethanol drinking.** A large number of studies have previously demonstrated that the CeA is necessary for elevated ethanol intake in ethanol dependent animals. Therefore, the next set of studies leveraged this CeA-dependent behavior to assess the efficacy of DCZ for chemogenetic inhibition to reduce ethanol intake. As shown in Fig. 3A, chronic intermittent ethanol (CIE) exposure produces robust escalation of ethanol intake in dependent rats. A mixed-effects ANOVA with drinking session and exposure condition as factors revealed significant main effects of session ($F(2.248,21.73) = 4.330, p = 0.0227$) and condition ($F(1, 10) = 9.759, p = 0.0108$), and a significant session by condition interaction ($F(3,29) = 4.319, p = 0.0124$). Post-hoc analysis revealed that CIE-exposed rats exhibited significantly escalated ethanol intake starting in sessions 2 and 3, relative to their baseline intake (all $p$ values < 0.05), whereas intake by control rats exposed to air (AIR) remained unchanged (all $p$ values > 0.05). Following escalation of ethanol drinking, we tested the effects of chemogenetic inhibition via DCZ or CNO on ethanol intake (Fig. 3B). The mixed-effects ANOVA with drug and exposure condition as factors revealed main effects of drug treatment ($F(2.241,19.42) = 16.87, p < 0.0001$) and exposure condition ($F(1,10) = 34.43, p = 0.0002$). Post-
hoc analysis revealed that DCZ and CNO reduced ethanol intake in dependent and non-dependent rats to a similar magnitude, relative to their vehicle controls, saline and DMSO, respectively (all p values < 0.05). We also assessed whether the DCZ-mediated reduction in ethanol drinking was associated with a reduction in blood ethanol concentrations (BECs) (Fig. 3C). A paired t-test revealed that DCZ-treated rats exhibited a significant reduction in BECs (t=6.988, p=0.0002) suggesting that DCZ-mediated chemogenetic inhibition of the CeA produces physiologically relevant reductions in ethanol intake. To control for potential effects of DCZ alone on ethanol intake we assessed the escalated drinking phenotype in a separate cohort of animals expressing hM4Di or a control virus (mCherry) in the CeA. A mixed effects ANOVA with drug and virus as factors revealed a significant main effect of drug (F(3,30)=4.387, p=0.0113) and a significant drug by virus interaction (F(3, 30)=2.981, p=0.0470). Post-hoc analysis revealed that in hM4Di-expressing rats DCZ significantly reduced ethanol intake relative to its saline vehicle (p<0.05). In contrast, ethanol intake in mCherry controls was unaltered by DCZ treatment (p>0.05). In addition, in hM4Di-expressing animals, 0.1 mg/kg CNO failed to alter ethanol intake, relative to DMSO control (p>0.05), at a dose equal to an effective DCZ dose. Together, these results demonstrate that DCZ supports chemogenetic inhibition of a CeA-dependent behavior and provides evidence that DCZ has a significantly stronger effect than CNO.

**DCZ alone does not alter gross locomotor activity or induce place preference/aversion.** The next set of studies examined whether systemic administration of DCZ alone is associated with non-specific behavioral effects that have been observed with CNO. Toward that end, we assessed the effects of DCZ on locomotor activity (Fig. 4A-B) and place conditioning (Fig. 4C-D) in naïve rats not expressing DREADDs. A mixed-effects ANOVA of locomotor activity with time and drug treatment as factors revealed a significant main effect of time (F(6,664,79.96)=5.479, p<0.0001), but no significant main effect of drug (F(3,30)=1.100, p=0.3871) or drug treatment × time interaction (F(7,348)=1.191, p=0.1399). These results reveal that locomotor activity decreased across the 30-min session in all groups, regardless of drug treatment, suggesting that DCZ does not alter gross locomotor activity. A mixed-effects ANOVA of percent preference for the DCZ-paired side...
with time and session (Baseline vs Post-conditioning test) as factors yielded no significant main effect of time (F(2.857, 28.57) = 2.561, p = 0.0771), session (F(1,10) = 0.07812, p = 0.7856), or interaction (F(5,50) = 1.681, p = 0.1564), indicating that multiple injections of DCZ in animals without DREADDs is neither rewarding or aversive.

**Discussion**

The present study provides the first evidence of behavioral and slice electrophysiological efficacy of the DREADD ligand, DCZ, in rats. Our data show that a relatively low dose of DCZ (0.1 mg/kg) administered systemically effectively supports hM3Dq and hM4Di DREADD-mediated behavior and electrophysiological effects without apparent confounding, non-specific alterations in locomotor behavior or associative conditioning. Systemic administration of DCZ selectively induced robust cFos expression in hM3Dq-expressing neurons without producing any detectable cFos in the uninfected control hemisphere. In a slice electrophysiological preparation, DCZ effectively inhibited neuronal firing in hM4Di-expressing neurons. Moreover, DCZ produced greater inhibition of action potential firing at a lower concentration, compared to CNO. Systemic DCZ-mediated hM4Di inhibition reduced ethanol intake in ethanol dependent and non-dependent rats expressing hM4Di in the central amygdala. Lastly, systemic DCZ did not alter gross locomotor activity or produce a conditioned place preference/aversion in control animals that lacked DREADD expression, providing evidence that DCZ alone does not induce noticeable off-target behavioral alterations. Taken together, our findings suggest that DCZ is an effective ligand for use with hM3Dq and hM4Di DREADDs in rats and supports prior evidence that DCZ is a superior DREADD ligand that does not appear to produce off-target behavioral or physiological outcomes.

The goal of the hM3Dq cFos experiment was to assess whether DCZ could produce a robust and selective activation of cells expressing the excitatory DREADD, hM3Dq in rats. We chose cFos immunolabeling as the
readout because induction of cFos protein is a widely used index of neuronal activity with a temporally defined expression window\(^\text{14,15}\). DCZ-mediated activation of hM3Dq resulted in robust induction of cFos expression in hM3Dq-expressing cells, relative to saline controls, and did not induce any detectable cFos expression in the opposite non-injected control hemisphere. Because identical imaging settings were used for both hemispheres, it is possible that DCZ induced very low levels of cFos in the control hemisphere that we did not detect. However, given the robust staining in the virus hemisphere, any sparse cFos expression in other brain regions is likely negligible. Overall, results from this set of experiments reveal that systemically administered DCZ robustly and selectively activates hM3Dq-expressing neurons in vivo.

Prior studies that assessed hM4Di-mediated inhibition with CNO in slice electrophysiology applications typically monitored changes in membrane potential, action potential firing, rheobase, etc., and reported near-maximal inhibitory responses with 5 or 10 uM CNO\(^\text{14–19}\). The highest CNO concentration used in the present study was 1 uM, which produced ~40% inhibition of firing. This result appears appropriate relative to studies using 5 or tenfold higher CNO concentrations that appear to achieve near-maximal inhibition. However, the same concentration of DCZ (1 uM) produced ~75% percent inhibition, providing further support that DCZ offers better potency for hM4Di-mediation inhibition, relative to CNO.

For the hM4Di DCZ behavioral experiments, we chose to examine ethanol dependence-induced escalation of drinking as a number of previous studies have consistently demonstrated that the central amygdala is necessary for escalated intake in ethanol dependent animals\(^\text{20–22}\). To our knowledge, this is the first report to examine the effect of DREADD hM4Di inhibition of the central amygdala on dependence-induced escalation of drinking. While we observed that both DCZ and CNO-mediated hM4Di inhibition of the central amygdala reduced ethanol intake to a similar extent, DCZ was effective at a 100-fold lower dose. This finding is consistent with the slice electrophysiological observations of concentration differences and supports the contention that DCZ is a superior DREADD ligand\(^\text{13}\). In addition to a reduction in ethanol intake in dependent rats in response to systemic administration of either DCZ or CNO, we also observed a significant reduction in ethanol consumption in the non-dependent rats that had not undergone CIE exposure. A prior study reported a similar reduction in ethanol intake in non-dependent rats using a chemogenetic Dna02 inactivation approach to inhibit central amygdala neuronal ensembles\(^\text{23}\). Therefore, these observations are consistent with the suggestion that while global inhibition of the CeA may reduce ethanol intake regardless of dependence status, inhibition of specific cell-types and circuits in the CeA may selectively reduce ethanol intake in dependent rats\(^\text{20}\).

The present study also assessed whether systemic DCZ used in the prior experiments produced changes in gross locomotor behavior or was intrinsically rewarding/aversive in control rats lacking DREADD expression. Locomotor activity was utilized as it is a high-throughput assay that captures obvious changes in motor function. Furthermore, prior reports have observed changes in gross locomotor activity following administration of other DREADD ligands\(^\text{12,24}\). However, it should be noted that while we did not observe any gross changes in locomotor activity following administration of DCZ, we cannot rule out potential changes to fine locomotor movements that would be captured by more nuanced analyses.

To assess whether DCZ is intrinsically rewarding or aversive we used a place conditioning assay to determine whether repeated injections of DCZ paired with a distinct context could produce a place preference/aversion\(^\text{16,20}\). The results of these experiments revealed that DCZ did not support a conditioned place preference or aversion of the DCZ-paired compartment. Thus, systemic administration of the same low dose of DCZ that was shown to be an effective agonist of DREADD receptors in the cFos induction experiments, slice electrophysiological analysis of neuronal firing, and ethanol drinking, did not exhibit intrinsic rewarding or aversive properties. These control experiments provide encouraging evidence that DCZ alone does not produce obvious non-specific behavioral effects.

In summary, our findings demonstrate that systemic DCZ is effective for hM3Dq and hM4Di DREADD activation studies in rats. While the seminal publication on DCZ use was carried out in mice\(^\text{13}\), it is important to establish its effectiveness in rats to account for potential species differences in the response to DCZ and not simply rely of extrapolation of observations between species. For example, rats and mice have different sensitivities to the interoceptive effects of CNO and exhibit different metabolite profiles following clozapine and CNO administration\(^\text{10}\). Compared to other available DREADD ligands, DCZ is a promising tool with advantages including increased potency and lack of apparent off-target effects at concentrations that we demonstrate are effective in-vivo for DREADD activation. Moreover, DCZ provides a substantial cost savings benefit due to the low dose requirement relative to CNO and other DREADD ligands. Our observations in rats are consistent with the original findings in primates and mice\(^\text{13}\), that DCZ is a clear upgrade from past DREADD ligands and should provide researchers with an improved tool for DREADD activation.

Materials and methods

Animals. Adult male Long-Evans rats (\(N = 46\)) were obtained from Envigo (Indianapolis, IN). Upon arrival, animals were individually housed in standard polycarbonate cages within a temperature- and humidity-controlled vivarium, which was maintained on a reverse 12:12 light–dark cycle with lights off at 09:00. Rats were provided with Teklad 2918 (Envigo) standard chow and water ad libitum unless otherwise indicated. All experimental procedures were conducted with the approval of the Institutional Animal Care and Use Committee at the Medical University of South Carolina and adhered to the guidelines set forth by the National Research Council’s Guide for the Care and Use of Laboratory Animals. All methods and data are reported in accordance with ARRIVE guidelines (https://arriveguidelines.org) and recommendations.

Surgical procedures and viral vectors. Rats underwent stereotaxic surgery to inject either an excitatory (AAV8.hSyn.hM3Dq.mCherry; Addgene, catalog # 50,474-AAV8) or inhibitory (AAV8.hSyn.hM4Di.mCherry;
Addgene, catalog # 50.475-AAV8) DREADD, or mCherry control virus (AAV8.hSyn.mCherry; Addgene, catalog # 114,472-AAV8) into the central amygdala (AP: 2.2–2.4; ML: 4.2–4.3; DV: 7–6–7–8 from skull surface). For the cFos experiment, rats received unilateral injections of hM3Dq. All other experiments involved bilateral virus injections. Viruses were injected at a rate of 1 nL/sec for a total of 450 nL using a Hamilton syringe equipped to a micropump controller (World Precision Instruments, Micro4, UMC4). Syringes were slowly withdrawn after a 10-min diffusion period following injection. DREADD activation or inhibition testing began at least 4 weeks after surgery to allow adequate viral-mediated protein expression.

**DCZ-mediated excitatory DREADD induction of cFos expression.** Rats were habituated to handling and intraperitoneal (i.p.) injections of 0.9% saline for 3 consecutive days prior to injection of DCZ or saline. Deschloroclozapine (HelloBio, catalog # H91296) was dissolved in 0.9% saline and administered i.p. at a dose of 0.1 mg/kg for all behavioral experiments. Animals were sacrificed ~ 90 min following DCZ injection via transcardial perfusion with 1X PBS and 10% formalin. Extracted brains were post-fixed in 10% formalin for 24 h and transferred to 30% sucrose until tissue sectioning. A cryostat was used to obtain 40 μm tissue sections of the central amygdala, which was stored in 1X PBS + 0.1% NaNO₃ until immunofluorescent labeling.

Tissue sections were washed 3 times in 1X PBS for 5 min each, and then permeabilized in 1X PBS 0.4% Triton-X for 30 min. Tissue sections were then washed in blocking buffer (1X PBS + 0.2% Triton-X + 10% Normal Donkey Serum) for 1 h, and then incubated overnight at 4°C in blocking buffer + primary antibodies (rabbit anti-cFos, 1:1000 dilution, Synaptic Systems, catalog # 226 003; chicken anti-mCherry, 1:300 dilution, LSBio, catalog # LS-C204825). Following primary incubation, tissue is washed 10 times in 1X PBS for 1 min each and then incubated for 2 h in blocking buffer + secondary antibodies from Jackson Immunoresearch Laboratories (donkey anti-rabbit 488, catalog # 711-545-152; donkey anti-chicken, 1:500 dilution, catalog # 703-585-155). Upon completion of secondary incubation, tissue was washed 3 times in 1X PBS for 10 min each and stored in 1X PBS + 0.1% NaNO₃. Tissue was mounted on standard, positively charged microscope slides and coverslipped using ProLong Gold anti-fade mounting media with DAPI (Invitrogen, catalog # P36931).

Mounted tissue was imaged using a Zeiss LSM 880 confocal microscope. The 405, 488, and 561 nm lasers were used to obtain z-series images of DAPI, cFos, and hM3Dq-mCherry, respectively. Image acquisition settings (ie, laser power, gain, zoom) were identical for all images to enable proper comparison of cFos induction between hemispheres expressing or lacking hM3Dq expression. Exported image files were opened in ImageJ and the cell counter plugin was used to quantify the number of cFos + and mCherry + cells. Cell counts were performed by an individual blind to the experimental conditions.

**Slice electrophysiology recordings.** Brain slices containing the central amygdala (CeA) were obtained from rats at approximately PD 180. Rats were anesthetized using isoflurane and rapidly decapitated. The brain was then promptly removed and placed into room temperature N-Methyl-D-Glucamine (NMDG) based artificial cerebral spinal fluid (aCSF) consisting of (in mM): 93 NMDG, 2.5 KCl, 1.25 NaH₂PO₄, 30 NaHCO₃, 25 D-glucose, 20 HEPES, 2.5 C₅H₉NO₃S, 5 ascorbic acid, 10 MgCl₂, and 0.5 CaCl₂. Following slice preparation, slices were transferred to a submerged recording chamber held at 34°C and aerated with 5% CO₂/95% O₂. Slices were allowed to equilibrate for 1 s duration were applied beginning from −100 pA and continuing until > 6 action potentials were elicited. Using the current at which > 6 action potentials were evoked, further recordings were made to determine the effects of DCZ and CNO on neuronal excitability. This was done by recording baseline excitability at 1 min intervals for 2 min followed by recording excitability at 1 min intervals for 10 min during perfusion with increasing concentrations of CNO or DCZ. Recordings from multiple neurons were obtained and averaged for each animal.

**Chemogenetic inhibition of CeA neurons during dependence-escalated ethanol drinking.** Rats underwent a well-characterized model of ethanol dependence and withdrawal to assess dependence-induced escalated ethanol intake. This model has three consecutive phases: baseline ethanol drinking, chronic intermittent ethanol (CIE) exposure, and ethanol drinking during withdrawal. During baseline ethanol drinking, rats are given 24 h access to voluntarily consume 20% ethanol and water in their homecage for 4 weeks under an intermittent access 2-bottle choice (2BC) schedule. Rats then underwent CIE exposure, which involved 14 consecutive days of ethanol exposure by intermittent vapor inhalation. Each exposure day consisted of placing the animals in ethanol vapor chambers for 14 h followed by 10 h out of the chambers during which time the animals experience ethanol withdrawal. Control animals underwent similar transport and handling procedures but were exposed to room air instead of ethanol vapor (AIR-exposed). Following 2 weeks of CIE exposure, animals proceeded to the withdrawal drinking phase. During this phase, 3 days of CIE exposure were replaced with 3 days of 2BC withdrawal drinking, which consisted of 14 h access to 20% ethanol and water in the homecage beginning
10 h into withdrawal following removal from vapor chambers. Each withdrawal drinking day was preceded and followed by a day of CIE exposure. Chemogenetic inhibition test sessions began after the 1st week of withdrawal drinking to allow CIE-exposed rats to first achieve stable ethanol intake levels. DCZ, CNO, or vehicle injections occurred 30 min prior to the onset of withdrawal drinking and ethanol intake was measured 2 h after bottle onset. Test sessions were interleaved with at least one non-treatment drinking session to prevent any cumulative effects of repeated drug injections on ethanol intake. Tail-vein blood samples were collected 2 h after a DCZ-treated and non-drug treated session for determination of blood ethanol concentrations (BECs) using an Analox alcohol analyzer (Analox Instruments, Atlanta, GA).

**Place conditioning and locomotor activity tests.** A two-compartment place preference chamber (Med Associates, ENV-031C) was used to assess whether DCZ-elicited a conditioned place preference or aversion in control rats that had not undergone DREADD stereotaxic surgeries. Rats underwent a 30-min baseline preference test to assess any innate preference for either compartment. If a rat exhibited a baseline preference (> 60%), the preferred compartment was then paired with injections of DCZ. Otherwise, DCZ or vehicle (saline) injections were randomly paired with a specific compartment. Rats received three 30-min conditioning sessions for each drug-compartment pairing for a total of six consecutive conditioningsessions. Drug conditioning order was counterbalanced across animals and drug treatment alternated each day. One day after the final conditioning session, rats had a 30-min, drug-free test session to assess preference for the DCZ-paired compartment.

A separate group of rats was used to assess the effects of DCZ on gross locomotor activity (beam breaks) in the same apparatus used for place conditioning. On the first day, rats underwent a 30-min session to obtain a baseline measure of locomotor activity. The following 3 days consisted of saline, DCZ (0.1 mg/kg), and CNO (10 mg/kg) injections, respectively, 30–45 min prior to placement in the locomotor chambers. Beam breaks were assessed in 1-min bins across each 30-min session, in addition to session totals.

**Statistical analysis.** Mixed effects ANOVAs were used to analyze ethanol intake during dependence-escalated drinking, slice electrophysiology data comparing concentrations of DCZ and CNO on action potential firing, locomotor activity across time, total locomotor activity between drug treatment groups, and preference across time. T-tests were used to analyze cell counts between saline and DCZ-treated rats, BECs between baseline and DCZ drinking sessions in CIE-exposed rats, slice electrophysiology data assessing effects of DCZ or CNO on number of action potentials relative to baseline, and preference during baseline and post-conditioning tests in the DCZ place conditioning experiment. Bonferroni corrections were applied to all post-hoc analyses to correct for multiple comparisons following significant main effects or interactions. All data were analyzed using GraphPad Prism 9.0 software. Data are presented as means±SEM, and effects were considered statistically significant at p≤0.05.

**Data availability**

Any data generated from these studies that is not included in the present article is available upon request.

Received: 28 October 2021; Accepted: 6 April 2022

Published online: 21 April 2022

**References**

1. Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S. & Roth, B. L. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. *Proc. Natl. Acad. Sci.* **104**, 5163–5168 (2007).
2. Urban, D. J. & Roth, B. L. DREADDs (Designer Receptors Exclusively Activated by Designer Drugs): Chemogenetic tools with therapeutic utility. *Annu. Rev. Pharmacol. Toxicol.* **55**, 399–417 (2015).
3. Atasoy, D. & Sterrson, S. M. Chemogenetic tools for causal cellular and neuronal biology. *Physiol. Rev.* **98**, 391–418 (2018).
4. Roth, B. L. DREADDs for neuroscientists. *Neuron* **89**, 683–694 (2016).
5. Burnett, C. J. & Krashes, M. J. Resolving behavioral output via chemogenetic designer receptors exclusively activated by designer drugs. *J. Neurosci.* **36**, 9268–9282 (2016).
6. Raper, L. et al. Chemogenetic inhibition of the amygdala modulates emotional behavior expression in infant rhesus monkeys. *Eneuro* **6**, ENEURO.0360.19.2019 (2019).
7. Upright, N. A. et al. Behavioral effect of chemogenetic inhibition is directly related to receptor transduction levels in rhesus monkeys. *J. Neurosci.* **38**, 7969–7975 (2018).
8. Goutaudier, R., Coizet, V., Carnac, C. & Carnicella, S. DREADDs: The power of the lock, the weakness of the key. Favoring the pursuit of specific conditions rather than specific ligands. *Eneuro* **6**, ENEURO.0171-19.2019 (2019).
9. Jendryka, M. et al. Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice. *Sci. Rep.* **9**, 4522 (2019).
10. Gomez, J. L. et al. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. *Science* **357**, 503–507 (2017).
11. Manvich, D. F. et al. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice. *Sci. Rep.* **8**, 3840 (2018).
12. MacLaren, D. A. A. et al. Clozapine N-oxide administration produces behavioral effects in long-evans rats: Implications for designing DREADD experiments. *Eneuro* **3**, ENEURO.0219-16.2016 (2016).
13. Nagai, Y. et al. Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys. *Nat. Neurosci.* **23**, 1157–1167 (2020).
14. Draganow, M. & Faul, R. The use of c-fos as a metabolic marker in neuronal pathway tracing. *J. Neurosci. Methods* **29**, 261–265 (1989).
15. Kovács, K. J. Measurement of immediate-early gene activation-c-fos and beyond. *J. Neuroendocrinol.* **20**, 665–672 (2008).
16. Anderson, R. L. et al. Dynorphin-kappa opioid receptor activity in the central amygdala modulates binge-like alcohol drinking in mice. *Neuropsychopharmacology* **44**, 1084–1092 (2019).
17. Buchta, W. C., Mahler, S. V., Harlan, B., Aston-Jones, G. S. & Riegel, A. C. Dopamine terminals from the ventral tegmental area gate intrinsic inhibition in the prefrontal cortex. *Physiol. Rep.* **5**, e13198 (2017).
18. Li, H. *et al.* Experience-dependent modification of a central amygdala fear circuit. *Nat. Neurosci.* **16**, 332–339 (2013).
19. Li, M. M. *et al.* The paraventricular hypothalamus regulates satiety and prevents obesity via two genetically distinct circuits. *Neuron* **102**, 653-667.e6 (2019).
20. de Guglielmo, G. *et al.* Inactivation of a CRF-dependent amygdalofugal pathway reverses addiction-like behaviors in alcohol-dependent rats. *Nat. Commun.* **10**, 1238 (2019).
21. Hyytiä, P. & Koob, G. F. GABAA receptor antagonism in the extended amygdala decreases ethanol self-administration in rats. *Eur. J. Pharmacol.* **283**, 151–159 (1995).
22. Vendruscolo, L. F. & Roberts, A. J. Operant alcohol self-administration in dependent rats: Focus on the vapor model. *Alcohol* **48**, 277–286 (2014).
23. de Guglielmo, G. *et al.* Recruitment of a neuronal ensemble in the central nucleus of the amygdala is required for alcohol dependence. *J. Neurosci.* **36**, 9446–9453 (2016).
24. Ilg, A.-K., Enkel, T., Bartsch, D. & Rühner, F. Behavioral effects of acute systemic low-dose clozapine in wild-type rats: Implications for the use of DREADDs in behavioral neuroscience. *Front. Behav. Neurosci.* **12**, 173 (2018).
25. Cunningham, C. L., Gremel, C. M. & Groblewski, P. A. Drug-induced conditioned place preference and aversion in mice. *Nat. Protoc.* **1**, 1662–1670 (2006).
26. McKendrick, G. & Graziane, N. M. Drug-induced conditioned place preference and its practical use in substance use disorder research. *Front. Behav. Neurosci.* **14**, 582147 (2020).
27. Schindelin, J. *et al.* Fiji: An open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012).
28. Simms, J. A. *et al.* Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. *Alcohol. Clin. Exp. Res.* **32**, 1816–1823 (2008).

**Acknowledgements**

This work was supported by funding from the National Institutes on Alcohol Abuse and Alcoholism Grants AA019967 and AA027706 (LJC), T32 AA007474 (TBN, JDO), and F31 AA029622 (TBN).

**Author contributions**

T.B.N.: Conceived the experimental studies, performed behavioral experiments, analyzed data, interpreted findings, and drafted the manuscript. J.D.O.: Performed slice electrophysiological experiments and analysis, assisted with study design and drafting of manuscript. D.T.V.: Assisted with behavioral experiments and data analysis. L.J.C.: Conceived the experimental studies, assisted with interpretation of findings and drafting of the manuscript. All authors read and approved the final manuscript for publication.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Correspondence and requests for materials should be addressed to L.J.C.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022